nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0703	0.106	CbGbCtD
Tacrolimus—ALB—Prednisone—ankylosing spondylitis	0.0699	0.105	CbGbCtD
Tacrolimus—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0603	0.0907	CbGbCtD
Tacrolimus—CYP3A7—Dexamethasone—ankylosing spondylitis	0.0467	0.0702	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Dexamethasone—ankylosing spondylitis	0.0467	0.0702	CbGbCtD
Tacrolimus—ABCB1—Betamethasone—ankylosing spondylitis	0.0392	0.0589	CbGbCtD
Tacrolimus—ABCB1—Prednisolone—ankylosing spondylitis	0.0387	0.0582	CbGbCtD
Tacrolimus—ABCB1—Prednisone—ankylosing spondylitis	0.0366	0.0549	CbGbCtD
Tacrolimus—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0362	0.0543	CbGbCtD
Tacrolimus—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0351	0.0527	CbGbCtD
Tacrolimus—ALB—Methotrexate—ankylosing spondylitis	0.0351	0.0527	CbGbCtD
Tacrolimus—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0274	0.0412	CbGbCtD
Tacrolimus—CYP3A4—Betamethasone—ankylosing spondylitis	0.0235	0.0353	CbGbCtD
Tacrolimus—CYP3A4—Prednisolone—ankylosing spondylitis	0.0232	0.0348	CbGbCtD
Tacrolimus—ABCB1—Dexamethasone—ankylosing spondylitis	0.0228	0.0343	CbGbCtD
Tacrolimus—CYP3A4—Prednisone—ankylosing spondylitis	0.0219	0.0329	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—ankylosing spondylitis	0.0183	0.0276	CbGbCtD
Tacrolimus—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0137	0.0205	CbGbCtD
Tacrolimus—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000174	0.00052	CcSEcCtD
Tacrolimus—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000173	0.000519	CcSEcCtD
Tacrolimus—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000173	0.000519	CcSEcCtD
Tacrolimus—Epistaxis—Methotrexate—ankylosing spondylitis	0.000173	0.000519	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000173	0.000519	CcSEcCtD
Tacrolimus—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000173	0.000518	CcSEcCtD
Tacrolimus—Mental disorder—Prednisone—ankylosing spondylitis	0.000173	0.000518	CcSEcCtD
Tacrolimus—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000173	0.000517	CcSEcCtD
Tacrolimus—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000172	0.000515	CcSEcCtD
Tacrolimus—Erythema—Prednisone—ankylosing spondylitis	0.000172	0.000514	CcSEcCtD
Tacrolimus—Malnutrition—Prednisone—ankylosing spondylitis	0.000172	0.000514	CcSEcCtD
Tacrolimus—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000172	0.000514	CcSEcCtD
Tacrolimus—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000171	0.000513	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000171	0.000512	CcSEcCtD
Tacrolimus—Convulsion—Betamethasone—ankylosing spondylitis	0.000171	0.000512	CcSEcCtD
Tacrolimus—Convulsion—Dexamethasone—ankylosing spondylitis	0.000171	0.000512	CcSEcCtD
Tacrolimus—Hypertension—Betamethasone—ankylosing spondylitis	0.00017	0.00051	CcSEcCtD
Tacrolimus—Hypertension—Dexamethasone—ankylosing spondylitis	0.00017	0.00051	CcSEcCtD
Tacrolimus—Myalgia—Dexamethasone—ankylosing spondylitis	0.000168	0.000503	CcSEcCtD
Tacrolimus—Myalgia—Betamethasone—ankylosing spondylitis	0.000168	0.000503	CcSEcCtD
Tacrolimus—Anxiety—Betamethasone—ankylosing spondylitis	0.000167	0.000501	CcSEcCtD
Tacrolimus—Anxiety—Dexamethasone—ankylosing spondylitis	0.000167	0.000501	CcSEcCtD
Tacrolimus—Discomfort—Dexamethasone—ankylosing spondylitis	0.000166	0.000497	CcSEcCtD
Tacrolimus—Discomfort—Betamethasone—ankylosing spondylitis	0.000166	0.000497	CcSEcCtD
Tacrolimus—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000166	0.000496	CcSEcCtD
Tacrolimus—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000165	0.000495	CcSEcCtD
Tacrolimus—Pain—Prednisolone—ankylosing spondylitis	0.000165	0.000494	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000165	0.000494	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—ankylosing spondylitis	0.000165	0.000494	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000164	0.00049	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000163	0.000488	CcSEcCtD
Tacrolimus—Vision blurred—Prednisone—ankylosing spondylitis	0.000162	0.000485	CcSEcCtD
Tacrolimus—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000162	0.000484	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000162	0.000484	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000161	0.000483	CcSEcCtD
Tacrolimus—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000161	0.000482	CcSEcCtD
Tacrolimus—Oedema—Dexamethasone—ankylosing spondylitis	0.000161	0.000482	CcSEcCtD
Tacrolimus—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000161	0.000482	CcSEcCtD
Tacrolimus—Oedema—Betamethasone—ankylosing spondylitis	0.000161	0.000482	CcSEcCtD
Tacrolimus—Insomnia—Triamcinolone—ankylosing spondylitis	0.00016	0.00048	CcSEcCtD
Tacrolimus—Insomnia—Methylprednisolone—ankylosing spondylitis	0.00016	0.000479	CcSEcCtD
Tacrolimus—Infection—Dexamethasone—ankylosing spondylitis	0.00016	0.000479	CcSEcCtD
Tacrolimus—Infection—Betamethasone—ankylosing spondylitis	0.00016	0.000479	CcSEcCtD
Tacrolimus—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000159	0.000477	CcSEcCtD
Tacrolimus—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000159	0.000477	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000159	0.000476	CcSEcCtD
Tacrolimus—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000159	0.000476	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—ankylosing spondylitis	0.000159	0.000476	CcSEcCtD
Tacrolimus—Anaemia—Prednisone—ankylosing spondylitis	0.000159	0.000475	CcSEcCtD
Tacrolimus—Shock—Betamethasone—ankylosing spondylitis	0.000158	0.000474	CcSEcCtD
Tacrolimus—Shock—Dexamethasone—ankylosing spondylitis	0.000158	0.000474	CcSEcCtD
Tacrolimus—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000158	0.000474	CcSEcCtD
Tacrolimus—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000158	0.000473	CcSEcCtD
Tacrolimus—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000158	0.000473	CcSEcCtD
Tacrolimus—Agitation—Prednisone—ankylosing spondylitis	0.000158	0.000473	CcSEcCtD
Tacrolimus—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000158	0.000472	CcSEcCtD
Tacrolimus—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000158	0.000472	CcSEcCtD
Tacrolimus—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000157	0.00047	CcSEcCtD
Tacrolimus—Tachycardia—Betamethasone—ankylosing spondylitis	0.000157	0.00047	CcSEcCtD
Tacrolimus—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000156	0.000468	CcSEcCtD
Tacrolimus—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000156	0.000467	CcSEcCtD
Tacrolimus—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000156	0.000467	CcSEcCtD
Tacrolimus—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000156	0.000466	CcSEcCtD
Tacrolimus—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000156	0.000466	CcSEcCtD
Tacrolimus—Malaise—Prednisone—ankylosing spondylitis	0.000155	0.000464	CcSEcCtD
Tacrolimus—Vertigo—Prednisone—ankylosing spondylitis	0.000154	0.000462	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—ankylosing spondylitis	0.000154	0.000461	CcSEcCtD
Tacrolimus—Syncope—Prednisone—ankylosing spondylitis	0.000154	0.000461	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—ankylosing spondylitis	0.000154	0.00046	CcSEcCtD
Tacrolimus—Anorexia—Betamethasone—ankylosing spondylitis	0.000153	0.000459	CcSEcCtD
Tacrolimus—Anorexia—Dexamethasone—ankylosing spondylitis	0.000153	0.000459	CcSEcCtD
Tacrolimus—Urticaria—Prednisolone—ankylosing spondylitis	0.000153	0.000459	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000153	0.000458	CcSEcCtD
Tacrolimus—Fatigue—Triamcinolone—ankylosing spondylitis	0.000153	0.000458	CcSEcCtD
Tacrolimus—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000153	0.000457	CcSEcCtD
Tacrolimus—Pain—Triamcinolone—ankylosing spondylitis	0.000152	0.000454	CcSEcCtD
Tacrolimus—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000151	0.000452	CcSEcCtD
Tacrolimus—Hypotension—Dexamethasone—ankylosing spondylitis	0.00015	0.00045	CcSEcCtD
Tacrolimus—Hypotension—Betamethasone—ankylosing spondylitis	0.00015	0.00045	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—ankylosing spondylitis	0.00015	0.000448	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000149	0.000446	CcSEcCtD
Tacrolimus—Convulsion—Prednisone—ankylosing spondylitis	0.000149	0.000446	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000149	0.000445	CcSEcCtD
Tacrolimus—Hypertension—Prednisone—ankylosing spondylitis	0.000148	0.000444	CcSEcCtD
Tacrolimus—Chills—Methotrexate—ankylosing spondylitis	0.000148	0.000443	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000147	0.000439	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000147	0.000439	CcSEcCtD
Tacrolimus—Arthralgia—Prednisone—ankylosing spondylitis	0.000146	0.000438	CcSEcCtD
Tacrolimus—Myalgia—Prednisone—ankylosing spondylitis	0.000146	0.000438	CcSEcCtD
Tacrolimus—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000146	0.000438	CcSEcCtD
Tacrolimus—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000146	0.000437	CcSEcCtD
Tacrolimus—Anxiety—Prednisone—ankylosing spondylitis	0.000146	0.000436	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—ankylosing spondylitis	0.000146	0.000436	CcSEcCtD
Tacrolimus—Insomnia—Dexamethasone—ankylosing spondylitis	0.000146	0.000436	CcSEcCtD
Tacrolimus—Insomnia—Betamethasone—ankylosing spondylitis	0.000146	0.000436	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000145	0.000435	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000145	0.000433	CcSEcCtD
Tacrolimus—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000145	0.000433	CcSEcCtD
Tacrolimus—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000145	0.000433	CcSEcCtD
Tacrolimus—Discomfort—Prednisone—ankylosing spondylitis	0.000144	0.000433	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—ankylosing spondylitis	0.000144	0.000433	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—ankylosing spondylitis	0.000144	0.00043	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—ankylosing spondylitis	0.000144	0.00043	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000142	0.000426	CcSEcCtD
Tacrolimus—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000142	0.000424	CcSEcCtD
Tacrolimus—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000142	0.000424	CcSEcCtD
Tacrolimus—Urticaria—Triamcinolone—ankylosing spondylitis	0.000141	0.000422	CcSEcCtD
Tacrolimus—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000141	0.000421	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000141	0.000421	CcSEcCtD
Tacrolimus—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00014	0.00042	CcSEcCtD
Tacrolimus—Oedema—Prednisone—ankylosing spondylitis	0.00014	0.00042	CcSEcCtD
Tacrolimus—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.00014	0.00042	CcSEcCtD
Tacrolimus—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00014	0.000419	CcSEcCtD
Tacrolimus—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00014	0.000419	CcSEcCtD
Tacrolimus—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00014	0.000419	CcSEcCtD
Tacrolimus—Infection—Prednisone—ankylosing spondylitis	0.000139	0.000417	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000139	0.000416	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000139	0.000416	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—ankylosing spondylitis	0.000139	0.000416	CcSEcCtD
Tacrolimus—Fatigue—Dexamethasone—ankylosing spondylitis	0.000139	0.000416	CcSEcCtD
Tacrolimus—Fatigue—Betamethasone—ankylosing spondylitis	0.000139	0.000416	CcSEcCtD
Tacrolimus—Shock—Prednisone—ankylosing spondylitis	0.000138	0.000413	CcSEcCtD
Tacrolimus—Pain—Betamethasone—ankylosing spondylitis	0.000138	0.000412	CcSEcCtD
Tacrolimus—Pain—Dexamethasone—ankylosing spondylitis	0.000138	0.000412	CcSEcCtD
Tacrolimus—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000137	0.000412	CcSEcCtD
Tacrolimus—Tachycardia—Prednisone—ankylosing spondylitis	0.000137	0.00041	CcSEcCtD
Tacrolimus—Skin disorder—Prednisone—ankylosing spondylitis	0.000136	0.000408	CcSEcCtD
Tacrolimus—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000136	0.000406	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—ankylosing spondylitis	0.000135	0.000405	CcSEcCtD
Tacrolimus—Anorexia—Prednisone—ankylosing spondylitis	0.000134	0.0004	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000133	0.000399	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—ankylosing spondylitis	0.000133	0.000397	CcSEcCtD
Tacrolimus—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000133	0.000397	CcSEcCtD
Tacrolimus—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000133	0.000397	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000132	0.000394	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000132	0.000394	CcSEcCtD
Tacrolimus—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000131	0.000391	CcSEcCtD
Tacrolimus—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00013	0.000391	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—ankylosing spondylitis	0.000129	0.000388	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—ankylosing spondylitis	0.000129	0.000386	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—ankylosing spondylitis	0.000128	0.000385	CcSEcCtD
Tacrolimus—Urticaria—Betamethasone—ankylosing spondylitis	0.000128	0.000383	CcSEcCtD
Tacrolimus—Urticaria—Dexamethasone—ankylosing spondylitis	0.000128	0.000383	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000128	0.000382	CcSEcCtD
Tacrolimus—Dizziness—Prednisolone—ankylosing spondylitis	0.000128	0.000382	CcSEcCtD
Tacrolimus—Asthenia—Triamcinolone—ankylosing spondylitis	0.000127	0.000381	CcSEcCtD
Tacrolimus—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000127	0.000381	CcSEcCtD
Tacrolimus—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000127	0.000381	CcSEcCtD
Tacrolimus—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000127	0.000381	CcSEcCtD
Tacrolimus—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000127	0.000381	CcSEcCtD
Tacrolimus—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000127	0.00038	CcSEcCtD
Tacrolimus—Insomnia—Prednisone—ankylosing spondylitis	0.000127	0.00038	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisone—ankylosing spondylitis	0.000126	0.000377	CcSEcCtD
Tacrolimus—Pruritus—Triamcinolone—ankylosing spondylitis	0.000126	0.000376	CcSEcCtD
Tacrolimus—Cough—Methotrexate—ankylosing spondylitis	0.000125	0.000375	CcSEcCtD
Tacrolimus—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000125	0.000375	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—ankylosing spondylitis	0.000124	0.000372	CcSEcCtD
Tacrolimus—Dyspepsia—Prednisone—ankylosing spondylitis	0.000123	0.00037	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—ankylosing spondylitis	0.000122	0.000366	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—ankylosing spondylitis	0.000122	0.000366	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—ankylosing spondylitis	0.000122	0.000366	CcSEcCtD
Tacrolimus—Decreased appetite—Prednisone—ankylosing spondylitis	0.000122	0.000365	CcSEcCtD
Tacrolimus—Rash—Prednisolone—ankylosing spondylitis	0.000122	0.000364	CcSEcCtD
Tacrolimus—Dermatitis—Prednisolone—ankylosing spondylitis	0.000122	0.000364	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000121	0.000363	CcSEcCtD
Tacrolimus—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000121	0.000363	CcSEcCtD
Tacrolimus—Fatigue—Prednisone—ankylosing spondylitis	0.000121	0.000362	CcSEcCtD
Tacrolimus—Headache—Prednisolone—ankylosing spondylitis	0.000121	0.000362	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—ankylosing spondylitis	0.000121	0.000362	CcSEcCtD
Tacrolimus—Constipation—Prednisone—ankylosing spondylitis	0.00012	0.000359	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—ankylosing spondylitis	0.000118	0.000354	CcSEcCtD
Tacrolimus—Dizziness—Triamcinolone—ankylosing spondylitis	0.000117	0.000351	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000117	0.000351	CcSEcCtD
Tacrolimus—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000117	0.000351	CcSEcCtD
Tacrolimus—Infection—Methotrexate—ankylosing spondylitis	0.000116	0.000349	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000116	0.000346	CcSEcCtD
Tacrolimus—Asthenia—Dexamethasone—ankylosing spondylitis	0.000115	0.000346	CcSEcCtD
Tacrolimus—Asthenia—Betamethasone—ankylosing spondylitis	0.000115	0.000346	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000115	0.000344	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000115	0.000343	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000115	0.000343	CcSEcCtD
Tacrolimus—Nausea—Prednisolone—ankylosing spondylitis	0.000115	0.000343	CcSEcCtD
Tacrolimus—Pruritus—Betamethasone—ankylosing spondylitis	0.000114	0.000341	CcSEcCtD
Tacrolimus—Pruritus—Dexamethasone—ankylosing spondylitis	0.000114	0.000341	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—ankylosing spondylitis	0.000114	0.000341	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000113	0.000339	CcSEcCtD
Tacrolimus—Vomiting—Triamcinolone—ankylosing spondylitis	0.000113	0.000338	CcSEcCtD
Tacrolimus—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000113	0.000337	CcSEcCtD
Tacrolimus—Rash—Triamcinolone—ankylosing spondylitis	0.000112	0.000335	CcSEcCtD
Tacrolimus—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000112	0.000335	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—ankylosing spondylitis	0.000112	0.000334	CcSEcCtD
Tacrolimus—Rash—Methylprednisolone—ankylosing spondylitis	0.000112	0.000334	CcSEcCtD
Tacrolimus—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000112	0.000334	CcSEcCtD
Tacrolimus—Urticaria—Prednisone—ankylosing spondylitis	0.000111	0.000333	CcSEcCtD
Tacrolimus—Headache—Triamcinolone—ankylosing spondylitis	0.000111	0.000333	CcSEcCtD
Tacrolimus—Headache—Methylprednisolone—ankylosing spondylitis	0.000111	0.000332	CcSEcCtD
Tacrolimus—Body temperature increased—Prednisone—ankylosing spondylitis	0.000111	0.000332	CcSEcCtD
Tacrolimus—Abdominal pain—Prednisone—ankylosing spondylitis	0.000111	0.000332	CcSEcCtD
Tacrolimus—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00011	0.00033	CcSEcCtD
Tacrolimus—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00011	0.00033	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—ankylosing spondylitis	0.000109	0.000328	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000107	0.00032	CcSEcCtD
Tacrolimus—Dizziness—Dexamethasone—ankylosing spondylitis	0.000106	0.000319	CcSEcCtD
Tacrolimus—Dizziness—Betamethasone—ankylosing spondylitis	0.000106	0.000319	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—ankylosing spondylitis	0.000106	0.000317	CcSEcCtD
Tacrolimus—Nausea—Triamcinolone—ankylosing spondylitis	0.000105	0.000316	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000105	0.000315	CcSEcCtD
Tacrolimus—Nausea—Methylprednisolone—ankylosing spondylitis	0.000105	0.000315	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000104	0.000313	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—ankylosing spondylitis	0.000104	0.000312	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000103	0.000309	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000103	0.000309	CcSEcCtD
Tacrolimus—Vomiting—Dexamethasone—ankylosing spondylitis	0.000102	0.000306	CcSEcCtD
Tacrolimus—Vomiting—Betamethasone—ankylosing spondylitis	0.000102	0.000306	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000102	0.000305	CcSEcCtD
Tacrolimus—Rash—Betamethasone—ankylosing spondylitis	0.000101	0.000304	CcSEcCtD
Tacrolimus—Rash—Dexamethasone—ankylosing spondylitis	0.000101	0.000304	CcSEcCtD
Tacrolimus—Dermatitis—Betamethasone—ankylosing spondylitis	0.000101	0.000304	CcSEcCtD
Tacrolimus—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000101	0.000304	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000101	0.000303	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—ankylosing spondylitis	0.000101	0.000302	CcSEcCtD
Tacrolimus—Headache—Betamethasone—ankylosing spondylitis	0.000101	0.000302	CcSEcCtD
Tacrolimus—Headache—Dexamethasone—ankylosing spondylitis	0.000101	0.000302	CcSEcCtD
Tacrolimus—Asthenia—Prednisone—ankylosing spondylitis	0.000101	0.000301	CcSEcCtD
Tacrolimus—Pain—Methotrexate—ankylosing spondylitis	0.0001	0.0003	CcSEcCtD
Tacrolimus—Pruritus—Prednisone—ankylosing spondylitis	9.92e-05	0.000297	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—ankylosing spondylitis	9.65e-05	0.000289	CcSEcCtD
Tacrolimus—Diarrhoea—Prednisone—ankylosing spondylitis	9.59e-05	0.000287	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	9.58e-05	0.000287	CcSEcCtD
Tacrolimus—Nausea—Betamethasone—ankylosing spondylitis	9.56e-05	0.000286	CcSEcCtD
Tacrolimus—Nausea—Dexamethasone—ankylosing spondylitis	9.56e-05	0.000286	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—ankylosing spondylitis	9.31e-05	0.000279	CcSEcCtD
Tacrolimus—Dizziness—Prednisone—ankylosing spondylitis	9.27e-05	0.000278	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—ankylosing spondylitis	9.26e-05	0.000277	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—ankylosing spondylitis	9.26e-05	0.000277	CcSEcCtD
Tacrolimus—Vomiting—Prednisone—ankylosing spondylitis	8.91e-05	0.000267	CcSEcCtD
Tacrolimus—Rash—Prednisone—ankylosing spondylitis	8.84e-05	0.000265	CcSEcCtD
Tacrolimus—Dermatitis—Prednisone—ankylosing spondylitis	8.83e-05	0.000264	CcSEcCtD
Tacrolimus—Headache—Prednisone—ankylosing spondylitis	8.78e-05	0.000263	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—ankylosing spondylitis	8.63e-05	0.000258	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—ankylosing spondylitis	8.41e-05	0.000252	CcSEcCtD
Tacrolimus—Nausea—Prednisone—ankylosing spondylitis	8.33e-05	0.000249	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—ankylosing spondylitis	8.29e-05	0.000248	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—ankylosing spondylitis	8.02e-05	0.00024	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—ankylosing spondylitis	7.75e-05	0.000232	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—ankylosing spondylitis	7.45e-05	0.000223	CcSEcCtD
Tacrolimus—Rash—Methotrexate—ankylosing spondylitis	7.39e-05	0.000221	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—ankylosing spondylitis	7.38e-05	0.000221	CcSEcCtD
Tacrolimus—Headache—Methotrexate—ankylosing spondylitis	7.34e-05	0.00022	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—ankylosing spondylitis	6.96e-05	0.000208	CcSEcCtD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	2.89e-05	0.0664	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	2.76e-05	0.0633	CbGpPWpGaD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	2.24e-05	0.0514	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	2.09e-05	0.048	CbGpPWpGaD
Tacrolimus—PPP3CA—BCR signaling pathway—CD79A—ankylosing spondylitis	1.81e-05	0.0416	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IL12B—ankylosing spondylitis	9.62e-06	0.0221	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL1A—ankylosing spondylitis	9.45e-06	0.0217	CbGpPWpGaD
Tacrolimus—PPP3CA—Amyotrophic lateral sclerosis (ALS)—TNF—ankylosing spondylitis	8.85e-06	0.0203	CbGpPWpGaD
Tacrolimus—MTOR—Leptin signaling pathway—IL1RN—ankylosing spondylitis	8.22e-06	0.0189	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TLR4—ankylosing spondylitis	7.57e-06	0.0174	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KIR3DL1—ankylosing spondylitis	7.49e-06	0.0172	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL1A—ankylosing spondylitis	7.32e-06	0.0168	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	7.12e-06	0.0164	CbGpPWpGaD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	7.02e-06	0.0161	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—CD40LG—ankylosing spondylitis	6.85e-06	0.0157	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—IL10—ankylosing spondylitis	6.85e-06	0.0157	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CARD9—ankylosing spondylitis	6.76e-06	0.0155	CbGpPWpGaD
Tacrolimus—PPP3CA—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	6.58e-06	0.0151	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	6.2e-06	0.0142	CbGpPWpGaD
Tacrolimus—MTOR—Type II diabetes mellitus—TNF—ankylosing spondylitis	5.98e-06	0.0137	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TLR4—ankylosing spondylitis	5.87e-06	0.0135	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	5.39e-06	0.0124	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ANTXR2—ankylosing spondylitis	5.24e-06	0.012	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—ankylosing spondylitis	5.18e-06	0.0119	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—TNF—ankylosing spondylitis	4.93e-06	0.0113	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HLA-C—ankylosing spondylitis	4.76e-06	0.0109	CbGpPWpGaD
Tacrolimus—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	4.69e-06	0.0108	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL1R2—ankylosing spondylitis	4.54e-06	0.0104	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	4.52e-06	0.0104	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ERAP1—ankylosing spondylitis	4.3e-06	0.00988	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HLA-C—ankylosing spondylitis	4.24e-06	0.00975	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ANTXR2—ankylosing spondylitis	4.07e-06	0.00934	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CARD9—ankylosing spondylitis	3.94e-06	0.00904	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	3.91e-06	0.00898	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	3.58e-06	0.00821	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TNF—ankylosing spondylitis	3.57e-06	0.00821	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—CD79A—ankylosing spondylitis	3.36e-06	0.00772	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	3.32e-06	0.00763	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	3.31e-06	0.0076	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KIR3DL1—ankylosing spondylitis	3.27e-06	0.0075	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ERAP1—ankylosing spondylitis	3.09e-06	0.00711	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—B3GNT2—ankylosing spondylitis	3.09e-06	0.0071	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CARD9—ankylosing spondylitis	2.95e-06	0.00677	CbGpPWpGaD
Tacrolimus—MTOR—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	2.87e-06	0.00659	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HLA-B—ankylosing spondylitis	2.82e-06	0.00647	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TNF—ankylosing spondylitis	2.77e-06	0.00637	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TNF—ankylosing spondylitis	2.69e-06	0.00619	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—CRP—ankylosing spondylitis	2.69e-06	0.00618	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.65e-06	0.00609	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PTGER4—ankylosing spondylitis	2.51e-06	0.00577	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HLA-B—ankylosing spondylitis	2.51e-06	0.00576	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-C—ankylosing spondylitis	2.47e-06	0.00568	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	2.44e-06	0.00561	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	2.43e-06	0.00558	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	2.43e-06	0.00558	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—B3GNT2—ankylosing spondylitis	2.4e-06	0.0055	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.32e-06	0.00533	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	2.31e-06	0.00531	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ANTXR2—ankylosing spondylitis	2.29e-06	0.00525	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CRP—ankylosing spondylitis	2.22e-06	0.00509	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—IL1A—ankylosing spondylitis	2.16e-06	0.00497	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL1RN—ankylosing spondylitis	2.15e-06	0.00493	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	2.14e-06	0.00492	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	2.14e-06	0.00491	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—TLR4—ankylosing spondylitis	2.13e-06	0.00488	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	2.05e-06	0.0047	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1R2—ankylosing spondylitis	1.98e-06	0.00455	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	1.89e-06	0.00433	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD79A—ankylosing spondylitis	1.89e-06	0.00433	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERAP1—ankylosing spondylitis	1.88e-06	0.00431	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HLA-C—ankylosing spondylitis	1.85e-06	0.00425	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—MMP3—ankylosing spondylitis	1.79e-06	0.00411	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-C—ankylosing spondylitis	1.78e-06	0.00408	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CARD9—ankylosing spondylitis	1.72e-06	0.00394	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL1A—ankylosing spondylitis	1.55e-06	0.00355	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD40LG—ankylosing spondylitis	1.54e-06	0.00353	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	1.5e-06	0.00344	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTGER4—ankylosing spondylitis	1.48e-06	0.00341	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-B—ankylosing spondylitis	1.46e-06	0.00336	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD79A—ankylosing spondylitis	1.36e-06	0.00311	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-A—ankylosing spondylitis	1.35e-06	0.00311	CbGpPWpGaD
Tacrolimus—MTOR—Disease—B3GNT2—ankylosing spondylitis	1.35e-06	0.00309	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CRP—ankylosing spondylitis	1.29e-06	0.00297	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HLA-A—ankylosing spondylitis	1.25e-06	0.00287	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—TLR4—ankylosing spondylitis	1.24e-06	0.00284	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TNF—ankylosing spondylitis	1.22e-06	0.0028	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTGER4—ankylosing spondylitis	1.15e-06	0.00264	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD40LG—ankylosing spondylitis	1.1e-06	0.00254	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HLA-B—ankylosing spondylitis	1.09e-06	0.00251	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-C—ankylosing spondylitis	1.08e-06	0.00248	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP3—ankylosing spondylitis	1.06e-06	0.00243	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-B—ankylosing spondylitis	1.05e-06	0.00241	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-A—ankylosing spondylitis	9.74e-07	0.00224	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HLA-A—ankylosing spondylitis	9.7e-07	0.00223	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	9.69e-07	0.00222	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CRP—ankylosing spondylitis	9.67e-07	0.00222	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1RN—ankylosing spondylitis	9.36e-07	0.00215	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TLR4—ankylosing spondylitis	9.27e-07	0.00213	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	9.25e-07	0.00212	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—B3GNT2—ankylosing spondylitis	8.91e-07	0.00205	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD79A—ankylosing spondylitis	8.22e-07	0.00189	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP3—ankylosing spondylitis	8.19e-07	0.00188	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1A—ankylosing spondylitis	6.74e-07	0.00155	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD40LG—ankylosing spondylitis	6.7e-07	0.00154	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTGER4—ankylosing spondylitis	6.47e-07	0.00149	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	6.44e-07	0.00148	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-B—ankylosing spondylitis	6.37e-07	0.00146	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-A—ankylosing spondylitis	5.91e-07	0.00136	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CRP—ankylosing spondylitis	5.63e-07	0.00129	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—B3GNT2—ankylosing spondylitis	5.54e-07	0.00127	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HLA-A—ankylosing spondylitis	5.45e-07	0.00125	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TLR4—ankylosing spondylitis	5.4e-07	0.00124	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	4.86e-07	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP3—ankylosing spondylitis	4.61e-07	0.00106	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	4.57e-07	0.00105	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.99e-07	0.000687	CbGpPWpGaD
